Understanding the spread and resistance of a dangerous bacteria called Klebsiella pneumoniae
Regional genomic epidemiology to identify drivers of resistance, transmission and infection with carbapenem-resistant Klebsiella pneumoniae
This study is looking into how a tough-to-treat bacteria called carbapenem-resistant Klebsiella pneumoniae spreads and becomes resistant to antibiotics, so we can find better ways to help patients who get infected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10758025 on NIH RePORTER |
What this research studies
This research investigates the factors that contribute to the emergence and spread of carbapenem-resistant Klebsiella pneumoniae (CRKP), a significant public health threat. By analyzing genetic data and epidemiological patterns, the study aims to identify how this bacteria transmits and develops resistance to antibiotics. The research will involve collaboration with healthcare networks to gather data on CRKP infections, which could lead to better prevention and treatment strategies for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include hospitalized patients who are at risk of or currently infected with carbapenem-resistant Klebsiella pneumoniae.
Not a fit: Patients who are not hospitalized or do not have any risk factors for CRKP infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for controlling and treating infections caused by carbapenem-resistant Klebsiella pneumoniae.
How similar studies have performed: Previous research has shown success in understanding antibiotic resistance through genomic epidemiology, indicating that this approach has potential for impactful findings.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Snitkin, Evan — University of Michigan at Ann Arbor
- Study coordinator: Snitkin, Evan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.